Core Viewpoint - The stock of Shandong Boyuan Pharmaceutical Chemical Co., Ltd. has experienced significant fluctuations, with a year-to-date increase of 151.82% but a recent decline of 3.42% over the last five trading days [1] Group 1: Company Overview - Shandong Boyuan Pharmaceutical Chemical Co., Ltd. was established on August 6, 2008, and is located in Shouguang City, Shandong Province [2] - The company specializes in the research, production, and sales of fine chemicals, including organic iodides, inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2] - The main revenue composition includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2] Group 2: Financial Performance - For the period from January to September 2025, Boyuan achieved operating revenue of 1.073 billion yuan, representing a year-on-year growth of 6.60% [2] - The net profit attributable to the parent company was 132 million yuan, showing a year-on-year decrease of 22.53% [2] - Cumulative cash dividends since the A-share listing amount to 88.408 million yuan [3] Group 3: Shareholder and Market Activity - As of October 20, 2025, the number of shareholders increased by 25.58% to 13,300, with an average of 2,502 circulating shares per person, a decrease of 20.37% [2] - The stock has appeared on the "Dragon and Tiger List" six times this year, with the most recent appearance on October 17, where it recorded a net buy of -20.2738 million yuan [1] - Major shareholders include various new institutional investors, with significant holdings from funds such as Zhonghang New Start Flexible Allocation Mixed A and Hong Kong Central Clearing Limited [3]
博苑股份跌2.01%，成交额2.11亿元，主力资金净流入557.69万元